Andere Sprachen Neuronetics, Inc.

Aktien

A2JPMY

US64131A1051

STIM

Medizinische Ausrüstung

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 11.06.2026			% 5 Tage	Veränd. 1. Jan.
1,310 ^USD	+5,65 %		-10,27 %	-5,07 %

02.06.	Neuronetics, Inc. gibt Ernennung von Robert Greene zum Senior Vice President Sales mit Wirkung zum 1. Juni 2026 bekannt	CI
22.05.	Neuronetics, Inc. ernennt Francis X. Brown III mit Wirkung zum 5. Mai 2026 zum Accounting Officer	CI

Andere Sprachen

02.06.	Neuronetics Appoints Robert Greene as Senior Vice President Sales
02.06.	Neuronetics, Inc. Announces Appointment of Robert Greene to Senior Vice President Sales, Effective June 1, 2026
02.06.	Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026
22.05.	Neuronetics, Inc. Appoints Francis X. Brown III as Interim Principal Financial Officer, Effective May 5, 2026
22.05.	Neuronetics, Inc. Appoints Francis X. Brown III as Accounting Officer, Effective as of May 5, 2026
14.05.	Neuronetics and Ant Neuro announce strategic collaboration to integrate neuronavigation with Neurostar TMS treatment
14.05.	Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment
14.05.	Neuronetics and Ant Neuro Enter Strategic Collaboration to Integrate Neuronavigation with Neurostar Tms Treatment
13.05.	Neuronetics Insider Bought Shares Worth $636,500, According to a Recent SEC Filing
05.05.	Neuronetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
05.05.	Neuronetics : STIM Corporate Presentation May 2026
05.05.	Neuronetics: Q1 Earnings Snapshot
05.05.	Neuronetics Reports First Quarter 2026 Financial and Operating Results
05.05.	Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2026
29.04.	Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
21.04.	Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call
13.04.	Optum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse Practitioners
13.04.	Neuronetics, Inc. Highlights Optum/UHC/UBH TMS Policy Expansion Enabling PMHNPs To Deliver NeuroStar Therapy Across 26 States And Washington D.C
08.04.	Jorey Chernett Issues a Letter to Neuronetics
07.04.	Global markets live: Microsoft, Amazon, JPMorgan, Netflix, Blackstone…
07.04.	Neuronetics Comments on Letter from Pointillist Family Office
07.04.	Neuronetics Inc - Board reviews Jorey Chernett letter and acknowledges shareholder engagement
06.04.	Neuronetics Inc initiates workforce reduction impacting up to 5% of employees
06.04.	Neuronetics announces chief financial officer transition
06.04.	Neuronetics Announces CFO Exit, Reaffirms Financial Guidance